Wexford Capital LP Purchases New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Wexford Capital LP acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 20,000 shares of the company's stock, valued at approximately $348,000.

Several other hedge funds also recently bought and sold shares of BCAX. Barclays PLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth $255,000. SG Americas Securities LLC bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $147,000. Spire Wealth Management bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $31,000. Rhumbline Advisers bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $331,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $701,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wedbush reissued an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a research report on Friday. Wall Street Zen downgraded Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Trading Down 40.8%

Bicara Therapeutics stock traded down $6.39 during midday trading on Friday, reaching $9.27. The company's stock had a trading volume of 7,204,269 shares, compared to its average volume of 532,519. The stock's 50-day simple moving average is $12.91 and its 200-day simple moving average is $14.89. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). On average, research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.